- Home
- ONCY vs OPTN Comparison
ONCY vs OPTN Comparison
Compare ONCY & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- OPTN
- Stock Information
- Founded
- ONCY 1998
- OPTN 2010
- Country
- ONCY Canada
- OPTN United States
- Employees
- ONCY N/A
- OPTN N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- ONCY Health Care
- OPTN Health Care
- Exchange
- ONCY Nasdaq
- OPTN Nasdaq
- Market Cap
- ONCY 56.2M
- OPTN 55.4M
- IPO Year
- ONCY 1999
- OPTN 2017
- Fundamental
- Price
- ONCY $0.73
- OPTN $5.77
- Analyst Decision
- ONCY Strong Buy
- OPTN Strong Buy
- Analyst Count
- ONCY 2
- OPTN 3
- Target Price
- ONCY $4.00
- OPTN $16.67
- AVG Volume (30 Days)
- ONCY 563.2K
- OPTN 18.7K
- Earning Date
- ONCY 03-06-2025
- OPTN 03-06-2025
- Dividend Yield
- ONCY N/A
- OPTN N/A
- EPS Growth
- ONCY N/A
- OPTN N/A
- EPS
- ONCY N/A
- OPTN N/A
- Revenue
- ONCY N/A
- OPTN $75,672,000.00
- Revenue This Year
- ONCY N/A
- OPTN $13.42
- Revenue Next Year
- ONCY N/A
- OPTN $38.54
- P/E Ratio
- ONCY N/A
- OPTN N/A
- Revenue Growth
- ONCY N/A
- OPTN 5.13
- 52 Week Low
- ONCY $0.67
- OPTN $4.82
- 52 Week High
- ONCY $1.53
- OPTN $31.50
- Technical
- Relative Strength Index (RSI)
- ONCY 40.10
- OPTN 44.78
- Support Level
- ONCY $0.71
- OPTN $5.20
- Resistance Level
- ONCY $0.79
- OPTN $6.49
- Average True Range (ATR)
- ONCY 0.04
- OPTN 0.50
- MACD
- ONCY 0.00
- OPTN 0.04
- Stochastic Oscillator
- ONCY 32.71
- OPTN 44.19
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.